Vamil Divan
Stock Analyst at Guggenheim
(4.85)
# 73
Out of 5,124 analysts
244
Total ratings
67.61%
Success rate
22.84%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $230 → $221 | $174.04 | +26.98% | 8 | Dec 18, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $206 → $227 | $206.95 | +9.69% | 18 | Dec 5, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $24.90 | +40.56% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $15.43 | +10.17% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.51 | +429.80% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $78.94 | +45.68% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.63 | +374.38% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $228.49 | +5.91% | 28 | Oct 20, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $6.03 | +82.42% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $8.86 | +46.73% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $34.01 | +14.67% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.24 | +212.50% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $327.31 | -12.01% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $5.77 | +939.86% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $105.26 | +9.25% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $38.21 | +23.00% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.49 | +186.53% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $50.64 | +20.46% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $20.36 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.83 | +438.30% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.10 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $26.71 | -28.87% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $141.83 | -30.90% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $27.98 | +21.52% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.19 | +356.62% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $182.64 | -73.17% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,074.68 | -66.87% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.85 | -23.57% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $11.29 | +1,264.04% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.65 | +125.56% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.68 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $31.21 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.70 | +94.81% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $53.94 | +13.09% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.70 | +2,683.78% | 3 | Jan 17, 2018 |
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $174.04
Upside: +26.98%
Johnson & Johnson
Dec 5, 2025
Maintains: Buy
Price Target: $206 → $227
Current: $206.95
Upside: +9.69%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $24.90
Upside: +40.56%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $15.43
Upside: +10.17%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.51
Upside: +429.80%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $78.94
Upside: +45.68%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.63
Upside: +374.38%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $228.49
Upside: +5.91%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.03
Upside: +82.42%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $8.86
Upside: +46.73%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $34.01
Upside: +14.67%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.24
Upside: +212.50%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $327.31
Upside: -12.01%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $5.77
Upside: +939.86%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $105.26
Upside: +9.25%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $38.21
Upside: +23.00%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.49
Upside: +186.53%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $50.64
Upside: +20.46%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $20.36
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.83
Upside: +438.30%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.10
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $26.71
Upside: -28.87%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $141.83
Upside: -30.90%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $27.98
Upside: +21.52%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.19
Upside: +356.62%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $182.64
Upside: -73.17%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,074.68
Upside: -66.87%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.85
Upside: -23.57%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $11.29
Upside: +1,264.04%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.65
Upside: +125.56%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $32.68
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $31.21
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.70
Upside: +94.81%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $53.94
Upside: +13.09%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.70
Upside: +2,683.78%